Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 5
2005 3
2006 3
2007 3
2008 9
2009 5
2010 5
2011 4
2012 7
2013 1
2014 2
2015 4
2016 6
2017 4
2018 3
2019 2
2020 7
2021 4
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
Linardou H, Lampaki S, Koliou GA, Vozikis A, Boutis A, Nikolaidi A, Kontogiorgos I, Papakotoulas P, Christopoulou A, Spyratos D, Bafaloukos D, Psyrri A, Grivas A, Koumarianou A, Tsiakitzis K, Mauri D, Rigakos G, Aravantinos G, Papantoniou P, Oikonomopoulos G, Fountzilas E, Koufaki MI, Kaparelou M, Liolis E, Mountzios G, Kosmidis P, Fountzilas G, Samantas E. Linardou H, et al. Among authors: kosmidis p. Anticancer Res. 2023 Jun;43(6):2799-2812. doi: 10.21873/anticanres.16449. Anticancer Res. 2023. PMID: 37247889
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzi D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. Mountzios G, et al. Among authors: kosmidis p. JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan. JTO Clin Res Rep. 2022. PMID: 36793384 Free PMC article.
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
Zagouri F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, Andrikopoulou Α, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri D, Koumarianou A, Petraki K, Tsipoura A, Pectasides D, Gogas H, Fountzilas G. Zagouri F, et al. Among authors: kosmidis p. Br J Cancer. 2022 Sep;127(4):695-703. doi: 10.1038/s41416-022-01846-y. Epub 2022 May 24. Br J Cancer. 2022. PMID: 35610366 Free PMC article. Clinical Trial.
Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.
Tzelves L, Manolitsis I, Varkarakis I, Ivanovic M, Kokkonidis M, Useros CS, Kosmidis T, Muñoz M, Grau I, Athanatos M, Vizitiu A, Lampropoulos K, Koutsouri T, Stefanatou D, Perrakis K, Stratigaki C, Autexier S, Kosmidis P, Valachis A. Tzelves L, et al. Among authors: kosmidis p. PLoS One. 2022 Apr 21;17(4):e0265127. doi: 10.1371/journal.pone.0265127. eCollection 2022. PLoS One. 2022. PMID: 35446854 Free PMC article.
Genetic Variation in the Vascular Endothelial Growth Factor (VEGFA) Gene at rs13207351 Is Associated with Overall Survival of Patients with Head and Neck Cancer.
Dimitrakopoulos FI, Koliou GA, Kotoula V, Papadopoulou K, Markou K, Vlachtsis K, Angouridakis N, Karasmanis I, Nikolaou A, Psyrri A, Visvikis A, Kosmidis P, Fountzilas G, Koutras A. Dimitrakopoulos FI, et al. Among authors: kosmidis p. Cancers (Basel). 2021 Mar 8;13(5):1163. doi: 10.3390/cancers13051163. Cancers (Basel). 2021. PMID: 33800431 Free PMC article.
Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer.
Ntzifa A, Strati A, Koliou GA, Zagouri F, Pectasides D, Pentheroudakis G, Christodoulou C, Gogas H, Magkou C, Petraki C, Kosmidis P, Aravantinos G, Kotoula V, Fountzilas G, Lianidou E. Ntzifa A, et al. Among authors: kosmidis p. Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):147-156. doi: 10.21873/cgp.20249. Cancer Genomics Proteomics. 2021. PMID: 33608311 Free PMC article. Review.
Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.
Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC. Fountzilas E, et al. Among authors: kosmidis p. Cancers (Basel). 2021 Jan 8;13(2):198. doi: 10.3390/cancers13020198. Cancers (Basel). 2021. PMID: 33429865 Free PMC article.
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Mountzios G, et al. Among authors: kosmidis p. Clin Lung Cancer. 2021 Mar;22(2):e180-e192. doi: 10.1016/j.cllc.2020.09.017. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33162330
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. Metro G, et al. Among authors: kosmidis p. J Immunother. 2020 Nov/Dec;43(9):299-306. doi: 10.1097/CJI.0000000000000340. J Immunother. 2020. PMID: 32991393
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Friedlaender A, et al. Among authors: kosmidis p. Acta Oncol. 2020 Sep;59(9):1058-1063. doi: 10.1080/0284186X.2020.1781249. Epub 2020 Jun 17. Acta Oncol. 2020. PMID: 32762415
78 results